Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRVO 
CervoMed Inc. (CRVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: CRVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $20
1 Year Target Price $20
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 131.1% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.89M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 7 | Beta -6.25 | 52 Weeks Range 1.80 - 19.50 | Updated Date 09/14/2025 |
52 Weeks Range 1.80 - 19.50 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -290.76% | Operating Margin (TTM) -376.41% |
Management Effectiveness
Return on Assets (TTM) -33.63% | Return on Equity (TTM) -54.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 43487897 | Price to Sales(TTM) 10.53 |
Enterprise Value 43487897 | Price to Sales(TTM) 10.53 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.64 | Shares Outstanding 8702720 | Shares Floating 5480108 |
Shares Outstanding 8702720 | Shares Floating 5480108 | ||
Percent Insiders 31.4 | Percent Institutions 23.56 |
Upturn AI SWOT
CervoMed Inc.
Company Overview
History and Background
CervoMed Inc. is a clinical-stage company focused on developing innovative therapies to treat neurological disorders, particularly those affecting cognitive function. Founded in 2017, CervoMed has advanced its lead compound, neflamapimod, through several clinical trials targeting early Alzheimer's disease and other neurodegenerative conditions. It's built its foundation on the science around p38MAP kinase inhibition to tackle synaptic dysfunction.
Core Business Areas
- Drug Development: Focuses on the development of novel therapies for neurological disorders, primarily Alzheimer's disease, by targeting synaptic dysfunction through p38MAP kinase inhibition.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its lead compound, neflamapimod, and other potential drug candidates in various patient populations.
- Research and Discovery: Engages in ongoing research and discovery efforts to identify new therapeutic targets and develop innovative approaches for treating neurological diseases.
Leadership and Structure
CervoMed Inc. is led by a team of experienced pharmaceutical executives and scientists. The company has a structured organizational framework, with departments dedicated to research, clinical development, regulatory affairs, and commercialization.
Top Products and Market Share
Key Offerings
- Neflamapimod: CervoMed's lead drug candidate is a small molecule inhibitor of p38MAP kinase. It is currently in Phase 2b clinical trials for the treatment of early Alzheimer's disease and potential other neurodegenerative disorders. Because it is in clinical trials, there is no revenue from this product and it has no market share. Competitors would be other companies developing drugs for Alzheimer's disease, such as Biogen (ADUHELM, LEQEMBI) and Eli Lilly (donanemab u2013 FDA approval pending).
Market Dynamics
Industry Overview
The pharmaceutical industry focused on neurological disorders is highly competitive and rapidly evolving. The growing aging population and increasing prevalence of conditions like Alzheimer's disease are driving demand for effective treatments.
Positioning
CervoMed is positioning itself as an innovator in the treatment of neurological diseases, particularly Alzheimer's disease, by targeting synaptic dysfunction. Its competitive advantage lies in its novel approach to p38MAP kinase inhibition and its focus on early-stage disease.
Total Addressable Market (TAM)
The global Alzheimer's disease market is projected to reach hundreds of billions of dollars in the coming years. CervoMed is targeting a subset of this market focused on early intervention and synaptic repair, potentially positioning them for significant market penetration if neflamapimod proves effective. Estimates suggest a potential multi-billion dollar opportunity if successful.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting synaptic dysfunction
- Experienced management team
- Strong intellectual property portfolio
- Focus on early-stage Alzheimer's disease
- Advancing neflamapimod through clinical trials
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks and uncertainties
- Reliance on a single lead compound (neflamapimod)
- No currently marketed products generating revenue
- High regulatory hurdles for drug approval
Opportunities
- Potential for breakthrough therapy designation and accelerated approval pathways
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion of neflamapimod to other neurological indications
- Growing demand for effective Alzheimer's treatments
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies with greater resources
- Failure of neflamapimod in clinical trials
- Adverse events or safety concerns related to neflamapimod
- Changes in regulatory landscape
- Pricing and reimbursement challenges
Competitors and Market Share
Key Competitors
- BIIB
- LLY
- ABBV
- ROSYY
Competitive Landscape
CervoMed faces competition from established pharmaceutical companies with greater resources. Its advantage lies in its unique therapeutic approach and focus on early-stage disease. Disadvantages come from the need to prove itself on the Alzheimer's platform.
Growth Trajectory and Initiatives
Historical Growth: CervoMed's historical growth is characterized by its progress in advancing neflamapimod through clinical development.
Future Projections: Future growth is dependent on the success of its clinical trials and its ability to secure partnerships or commercialize its products. Analyst estimates suggest significant upside potential if neflamapimod proves effective.
Recent Initiatives: Recent initiatives include the initiation and ongoing progress of its Phase 2b clinical trial of neflamapimod in early Alzheimer's disease, fundraising activities, and presentations at scientific conferences.
Summary
CervoMed is a high-risk, high-reward clinical-stage company focused on a novel approach to treating Alzheimer's disease. Its strength lies in its innovative therapeutic target and experienced leadership, but its success hinges on positive clinical trial results and securing sufficient funding. The company needs to carefully manage its cash burn and navigate the regulatory landscape, while positive data can create significant share value and allow for partnerships. Their p38MAP kinase approach differs from amyloid clearing drugs and can potentially be a good combination therapy
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CervoMed Inc.
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2016-01-04 | Co-Founder, CEO, President & Director Dr. John J. Alam M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15 | Website https://www.cervomed.com |
Full time employees 15 | Website https://www.cervomed.com | ||
CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.